22UA Stock Chart & Stats
CHF76.01
CHF0.93(1.24%)
At close: 4:00 PM EDT
CHF76.01
CHF0.93(1.24%)
Day’s Range― - ―
52-Week RangeCHF70.86 - CHF79.40
Previous CloseN/A
Volume26.00
Average Volume (3M)26.00
Market Cap
CHF18.92B
Enterprise ValueCHF6.84K
Total Cash (Recent Filing)CHF9.74B
Total Debt (Recent Filing)CHF315.97M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 03, 2026EPS Estimate
0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.73
Shares OutstandingN/A
10 Day Avg. Volume6
30 Day Avg. Volume26
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF100.76Price Target Upside32.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.68
Revenue Forecast (FY)CHF1.75B
Bulls Say, Bears Say
Bulls Say
Very Strong Balance Sheet And LiquidityEUR 16.6B of cash and very low leverage provide durable financial flexibility to fund late‑stage oncology trials, manufacturing scale-up, and M&A or partnerships without near‑term funding pressure. This supports multi‑year R&D investment and shields operations from cyclical revenue swings.
Advancing Late‑stage Oncology PipelineRobust Phase II signals and initiation/advancement of multiple pivotal Phase III programs (pumitamig, gotistobart, LCD) materially diversify revenue exposure beyond COVID vaccines. Successful registrational outcomes could create durable oncology franchises and recurring product revenues over several years.
MRNA Platform Commercialization ResilienceRegulatory approval for variant‑adapted vaccines and at‑risk manufacturing demonstrate platform credibility, regulatory relationships, and supply agility. These durable capabilities support recurring seasonal vaccine demand and strengthen BioNTech’s role as a preferred mRNA supplier long term.
Bears Say
Steep Revenue Reset From Peak COVID SalesRevenue has materially declined from pandemic peaks and remains lumpy; lower COVID vaccine demand reduces baseline topline and increases reliance on pipeline commercialization. Sustained lower product demand pressures margins and requires successful launches to restore prior revenue levels over multiple years.
Deteriorated Profitability And Rising Operating CostsHigh gross margins are offset by elevated R&D and SG&A, impairments, and restructuring, producing negative operating margins. If revenue growth from new products lags, the persistent cost base will depress returns and could erode equity capital over time despite the strong balance sheet.
Revenue Phasing And Concentration RiskLarge, discrete collaboration payments and H2 concentration create timing and recognition risk; delays or reclassification could materially shift reported results. This reduces near‑term revenue predictability and increases volatility in cash conversion and guidance reliability across reporting periods.
BioNTech SE News
22UA FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was CHF70.86 and its highest was CHF79.40 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is CHF18.92B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Nov 03, 2026 which is in 82 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Aug 04, 2026. The company reported -CHF3.028 earnings per share for the quarter, missing the consensus estimate of -CHF1.962 by -CHF1.065.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE does not currently pay dividends.
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is 0.69.
How many shares outstanding does BioNTech SE have?
Currently, no data Available
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -CHF3.028 in its last earnings report, missing expectations of -CHF1.962. Following the earnings report the stock price went down -2.958%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in CH:22UA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF100.76 (32.56% Upside)
CHF100.76 (32.56% Upside)
Blogger Sentiment
Bullish
CH:22UA Sentiment 78%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.43%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
22UA Company Deck
22UA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.View all CH:22UA earnings summaries22UA Stock 12 Month Forecast
Average Price Target
CHF100.76
▲(32.56% Upside)